Fn1 and JamL serve as prognostic biomarkers for breast and thyroid cancers, lung adenocarcinoma, and gastric cancer, while Ddit4 is a potential prognostic biomarker for colorectal cancer 27-32. Here, JAML is linked to thyroid cancer.